The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1
Abstract
BACKGROUND: Acute rejection is still a major problem in renal transplantation and is one of the most important causes of chronic graft dysfunction and late graft loss. Selective immunosuppression with a humanized antibody against the alpha-chain of the interleukin (IL)-2 receptor (CD25) was evaluated to demonstrate the efficacy of this type of immunoprophylaxis in combination with dual immunosuppression. METHODS: We studied the effect of daclizumab, a humanized monoclonal antibody against the alpha-chain of the IL-2 receptor, in a randomized double-blind, prospective phase III clinical trial in 275 patients receiving a first cadaveric renal allograft. Among them 111 (83%) in the placebo arm and 116 (82%) in the daclizumab arm received the full regimen of five doses (1.0 mg/kg) every other week. Baseline immunosuppression consisted of cyclosporine and corticosteroids. RESULTS: At 6 months, 39 (28%) of the patients in the daclizumab group had biopsy-proven rejections, as compared with 63 (47%) in the placebo group (P=0.001). The need for additional antilymphocyte therapy, antithymocyte globulin, antilymphocyte globulin (ATG, ALG, OKT3) was also lower in the daclizumab group (8% vs. 16%, P=0.02), and they required significantly lower mean (+/- SD) cumulative doses of prednisone (3750+/-1981 mg vs. 4438+/-2667 mg in the placebo group, P=0.01). Graft function was significantly better (P=0.02) in the daclizumab group (graft function rate: 58 vs. 51 ml/min, mean) as was patient survival (P=0.01, 99% vs. 94%). No specific adverse events were observed in daclizumab-treated patients. Patients receiving daclizumab experienced fewer cytomegalovirus infections (18% vs. 25%), and none died from severe infectious complications, compared to four patients in the placebo arm. No patient in the daclizumab group had a lymphoproliferative disorder or any other form of immunosuppression-related tumor during the first year after transplant. CONCLUSIONS: Administration of daclizumab in addition to dual immunosuppression therapy significantly reduced biopsy-proven acute rejection after renal transplantation, improved patient survival, and did not add to the toxicity of the immunosuppressive regimen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SOLLINGER, H. W. (1995) · Transplantation · doi:10.1097/00007890-199508000-00003 · Cited by 1,363
(1996) · Transplantation · doi:10.1097/00007890-199604150-00008 · Cited by 1,055
Grinyo, J. M., GROTH, C. G., Pichlmayr, R., Sadek, S., Vanrenterghem, Y. F. C., Behrend, M., Luck, R. P., Moreso, F., Peeters, J. A. G., Rodicio, J. L., et al. (1995) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 974
European Mycophenolate Mofetil Cooperative Study Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92534-1 · Cited by 927
Nashan, B., Moore, R., Amlot, P., Schmidt, A.-G., Abeywickrama, K., & Soulillou, J.-P. (1997) · The Lancet · doi:10.1016/s0140-6736(97)09278-7 · Cited by 749
Self-citationRobb, R. J., Greene, W. C., & Rusk, C. M. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.4.1126 · Cited by 725
Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., et al. (1997) · Transplantation · doi:10.1097/00007890-199708150-00012 · Cited by 724
Ortho Multicenter Transplant Study Group* (1985) · New England Journal of Medicine · doi:10.1056/nejm198508083130601 · Cited by 708
LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTS
ALMOND, P. S., MATAS, A., GILLINGHAM, K., DUNN, D. L., PAYNE, W. D., NAJARIAN, J. S., PAUL, G., & RAINER, G. (1993) · Transplantation · doi:10.1097/00007890-199304000-00013 · Cited by 660
A humanized antibody that binds to the interleukin 2 receptor.
Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10029 · Cited by 627
Cited by
Therapeutic monoclonal antibodies
Breedveld, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)01034-5 · Cited by 359
Dunn, C. J., Wagstaff, A. J., Perry, C. M., Plosker, G. L., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161130-00006 · Cited by 276
Interleukin 2 receptor antagonists for kidney transplant recipients
Webster, A. C., Ruster, L. P., McGee, R. G., Matheson, S. L., Higgins, G. Y., Willis, N. S., Chapman, J. R., & Craig, J. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003897.pub3 · Cited by 268
Interleukin‐2 in the development and control of inflammatory disease
Hoyer, K. K., Dooms, H., Barron, L., & Abbas, A. K. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00697.x · Cited by 262
Green, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229
Metadata
- Authors
- Nashan, B., Light, S., Hardie, I. R., Lin, A., & Johnson, J. R.
- Venue
- Transplantation
- Published
- 1999-01
- Volume
- 67
- Issue
- 1
- Pages
- 110-115
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1756759934
- Cited by
- 302
- References
- 23
- FWCI
- 28.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1. https://app.cochat.ai/papers/10.1097/00007890-199901150-00019
- The paper
- Nashan, B., Light, S., Hardie, I. R., Lin, A., & Johnson, J. R. (1999). REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1. Transplantation. https://doi.org/10.1097/00007890-199901150-00019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.